Research Analysts Offer Predictions for RNAC Q2 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at HC Wainwright lowered their Q2 2025 earnings estimates for shares of Cartesian Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.68) per share for the quarter, down from their prior estimate of ($0.67). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share. HC Wainwright also issued estimates for Cartesian Therapeutics' FY2025 earnings at ($2.80) EPS.

Separately, Needham & Company LLC dropped their price target on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $43.00.

Cartesian Therapeutics Price Performance

RNAC traded up $0.01 on Wednesday, hitting $9.16. The company had a trading volume of 53,651 shares, compared to its average volume of 115,218. Cartesian Therapeutics has a 52-week low of $8.85 and a 52-week high of $41.87. The stock has a fifty day simple moving average of $11.69 and a 200-day simple moving average of $16.28. The firm has a market capitalization of $237.74 million, a P/E ratio of -0.17 and a beta of 0.51.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The firm had revenue of $1.10 million for the quarter, compared to analysts' expectations of $0.69 million.

Hedge Funds Weigh In On Cartesian Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 683 Capital Management LLC grew its stake in Cartesian Therapeutics by 20.0% during the 1st quarter. 683 Capital Management LLC now owns 150,000 shares of the company's stock valued at $1,977,000 after purchasing an additional 25,000 shares during the last quarter. MPM Bioimpact LLC lifted its holdings in shares of Cartesian Therapeutics by 9.7% during the first quarter. MPM Bioimpact LLC now owns 790,779 shares of the company's stock worth $10,422,000 after purchasing an additional 69,640 shares during the period. AlphaQuest LLC purchased a new stake in Cartesian Therapeutics in the first quarter valued at approximately $95,000. Erste Asset Management GmbH increased its holdings in Cartesian Therapeutics by 49.8% in the 1st quarter. Erste Asset Management GmbH now owns 260,011 shares of the company's stock worth $3,432,000 after buying an additional 86,445 shares during the period. Finally, Twin Focus Capital Partners LLC raised its position in Cartesian Therapeutics by 25.0% during the 1st quarter. Twin Focus Capital Partners LLC now owns 15,000 shares of the company's stock worth $198,000 after buying an additional 3,000 shares during the last quarter. Hedge funds and other institutional investors own 86.95% of the company's stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.